ARCUTIS BIOTHERAPEUTICS, INC. Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year
ARCUTIS BIOTHERAPEUTICS, INC. (ARQT) had Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year of $188.00 thousand as of 2023-09-30, per its 10-Q filed 2023-11-03.
Discontinued › Notes
us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear · last filed 2023-11-03
- 2023-09-30: Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year $188.00K.
- 2023-06-30: Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year $374.00K.
- 2023-03-31: Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year $562.00K.
| Period end | Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year |
|---|---|
| 2023-09-30 | $188.00K 10-Q · filed 2023-11-03 |
| 2023-06-30 | $374.00K 10-Q · filed 2023-08-08 |
| 2023-03-31 | $562.00K 10-Q · filed 2023-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 |